Switch theme
Sign up to access all valuation multiples
Dis-Chem Pharmacies Ltd is a pharmaceutical company based in South Africa. Its product portfolio includes personal care products, beauty products, healthcare and nutrition products, and dispensary and baby care products. The operating segments of the group are Retail and Wholesale. It derives maximum revenue from the Retail segment, which includes company stores, retailers of pharmaceuticals and a variety of health and beauty products, as well as pharma-logistic services and oncology and retailers of pharmaceutical products. The Wholesale segment consists of the CJ wholesale and company distribution businesses, wholesalers of pharmaceuticals, and a variety of health and beauty products. Geographically, the group carries out its business operations principally in South Africa.
1978
20.6K+
LTM Revenue $2.2B
LTM EBITDA $176M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dis-Chem Pharmacies has a last 12-month revenue of $2.2B and a last 12-month EBITDA of $176M.
In the most recent fiscal year, Dis-Chem Pharmacies achieved revenue of $2.0B and an EBITDA of $159M.
Dis-Chem Pharmacies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dis-Chem Pharmacies valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8B | $2.0B | XXX | XXX | XXX |
| Gross Profit | $373M | $415M | XXX | XXX | XXX |
| Gross Margin | 21% | 21% | XXX | XXX | XXX |
| EBITDA | $152M | $159M | XXX | XXX | XXX |
| EBITDA Margin | 9% | 8% | XXX | XXX | XXX |
| Net Profit | $46.6M | $54.7M | XXX | XXX | XXX |
| Net Margin | 3% | 3% | XXX | XXX | XXX |
| Net Debt | $32.6M | $79.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Dis-Chem Pharmacies's stock price is ZAR 31 (or $2).
Dis-Chem Pharmacies has current market cap of ZAR 26.8B (or $1.5B), and EV of ZAR 31.3B (or $1.7B).
See Dis-Chem Pharmacies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.5B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Dis-Chem Pharmacies has market cap of $1.5B and EV of $1.7B.
Dis-Chem Pharmacies's trades at 0.8x LTM EV/Revenue multiple, and 9.7x LTM EBITDA.
Analysts estimate Dis-Chem Pharmacies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Dis-Chem Pharmacies and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | XXX | XXX |
| P/E | 24.0x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 21.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDis-Chem Pharmacies's NTM/LTM revenue growth is 11%
Dis-Chem Pharmacies's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $17K for the same period.
Over next 12 months, Dis-Chem Pharmacies's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Dis-Chem Pharmacies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Dis-Chem Pharmacies and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 20% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $17K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 17% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dis-Chem Pharmacies acquired XXX companies to date.
Last acquisition by Dis-Chem Pharmacies was XXXXXXXX, XXXXX XXXXX XXXXXX . Dis-Chem Pharmacies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Dis-Chem Pharmacies founded? | Dis-Chem Pharmacies was founded in 1978. |
| Where is Dis-Chem Pharmacies headquartered? | Dis-Chem Pharmacies is headquartered in South Africa. |
| How many employees does Dis-Chem Pharmacies have? | As of today, Dis-Chem Pharmacies has 20.6K+ employees. |
| Who is the CEO of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's CEO is Mr. Rui Manuel Morais. |
| Is Dis-Chem Pharmacies publicy listed? | Yes, Dis-Chem Pharmacies is a public company listed on JSE. |
| What is the stock symbol of Dis-Chem Pharmacies? | Dis-Chem Pharmacies trades under DCP ticker. |
| When did Dis-Chem Pharmacies go public? | Dis-Chem Pharmacies went public in 2016. |
| Who are competitors of Dis-Chem Pharmacies? | Similar companies to Dis-Chem Pharmacies include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's current market cap is $1.5B |
| What is the current revenue of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's last 12-month revenue is $2.2B. |
| What is the current EBITDA of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's last 12-month EBITDA is $176M. |
| What is the current EV/Revenue multiple of Dis-Chem Pharmacies? | Current revenue multiple of Dis-Chem Pharmacies is 0.8x. |
| What is the current EV/EBITDA multiple of Dis-Chem Pharmacies? | Current EBITDA multiple of Dis-Chem Pharmacies is 9.7x. |
| What is the current revenue growth of Dis-Chem Pharmacies? | Dis-Chem Pharmacies revenue growth between 2023 and 2024 was 11%. |
| Is Dis-Chem Pharmacies profitable? | Yes, Dis-Chem Pharmacies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
